尿激酶（2000 u CTA/kg/h）与肝素联合治疗引起的凝血参数改变。 - Suppr | 超能文献

Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin.

作者信息

Juhan I, Calas M F, Buonocore M, Mathieu P, Isnard G, Cazenave B, Serradimigni A

出版信息

Thromb Haemost. 1979 Oct 31;42(3):945-54.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin.尿激酶（2000 u CTA/kg/h）与肝素联合治疗引起的凝血参数改变。

Thromb Haemost. 1979 Oct 31;42(3):945-54.

2

Plasminogen and moderate doses of urokinase in the treatment of acute pulmonary embolism.纤溶酶原与中等剂量尿激酶治疗急性肺栓塞

Angiology. 1979 Jan;30(1):1-12. doi: 10.1177/000331977903000101.

3

[Combined use of heparin and urokinase in the patients with nephritis resistant to the conventional treatment and the significance of alpha 2-plasmin inhibitor in the therapy (author's transl)].肝素与尿激酶联合应用于常规治疗无效的肾炎患者及α2-纤溶酶抑制剂在治疗中的意义（作者译）

Rinsho Ketsueki. 1982 Mar;23(3):309-18.

4

Pretreatment with heparin in thrombolytic therapy with Urokinase. Heparin-urokinase therapy.尿激酶溶栓治疗中肝素预处理。肝素-尿激酶疗法。

Haemostasis. 1976;5(3):147-54. doi: 10.1159/000214130.

5

[Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].[肝素-尿激酶脉冲联合治疗小儿常规治疗抵抗性肾炎期间凝血和纤溶因子的变化]

Nihon Jinzo Gakkai Shi. 1993 Oct;35(10):1155-61.

6

[Biological profile of the 1st 4 hours of a thrombolytic treatment combining urokinase with lysyl-plasminogen].

Ann Biol Clin (Paris). 1985;43(6):851-5.

7

Role of alpha 2-plasmin inhibitor in the appearance of fibrinolytic activity during urokinase administration, and an evaluation of the optimal urokinase dosage.

Thromb Res. 1979;16(3-4):393-400. doi: 10.1016/0049-3848(79)90086-0.

8

Role of dextran sulfate in urokinase therapy and evaluation of the effects by estimation of plasmin inhibitor, fibrinogenolytic degradation products, and fibrinolytic degradation products.硫酸葡聚糖在尿激酶治疗中的作用以及通过纤溶酶抑制剂、纤维蛋白原降解产物和纤溶降解产物的评估来评价疗效

Jpn Heart J. 1982 May;23(3):339-47. doi: 10.1536/ihj.23.339.

9

Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.用尿激酶和链激酶治疗深静脉血栓形成期间的全身纤维蛋白溶解活性和抑制剂水平。

Thromb Haemost. 1983 Oct 31;50(3):664-8.

10

Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较

Thromb Haemost. 1981 Jun 30;45(3):225-9.

引用本文的文献

1

[Fibrinolytic therapy of lower limb deep vein thrombosis with urokinase (author's transl)].

Klin Wochenschr. 1982 May 17;60(10):489-96. doi: 10.1007/BF01756094.

2

Use of thrombolytic drugs in non-coronary disorders.溶栓药物在非冠状动脉疾病中的应用。

Drugs. 1989 Nov;38(5):801-21. doi: 10.2165/00003495-198938050-00006.